A dosimetric analysis of interstitial intensity modulated implants for pelvic recurrences, base of tongue and orbita tumors with specific references to the ICRU-58

GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology

“…The prescription dose is usually the minimum dose received by the CTV or a CTV surrogate (i.e., the D 90 > 100, V 100 > 90%). Dose inhomogeneities need to be minimized following general rules such as those derived from the Paris system [6,7] with additional optimization if needed, mainly by geometrical and graphical methods [8] which is possible in stepping source systems. A cautionary measure is to keep the hyperdose sleeves (200% isodose volumes) as thin as possible and not confluent with other applicator sleeves [6].…”

Three‐dimensional conformal brachytherapy boost in locally recurrent or residual cervical carcinoma: Does it impact clinical outcome?

“…The dose constraints were chosen to minimize the dose to the rectum, bladder and bowel, while delivering the adequate coverage to target volume delineated. Broadly, 2 mL volume of rectum and bladder should not receive more than 60% and 80% of the prescribed dose, respectively 16,17 . The algorithm selects the active dwell positions and determines the dwell time values to fulfill dose constraints applied on each target and organ at risk contoured.…”

“…1). The doses to the bladder, rectum and bowel were determined by the dose volume histogram (DVH) obtained from the TPS as according to the ICRU system requirements 16,18 . The biologically effective dose (BED) for radiobiological equivalence with standard conventional fractionation was calculated for PTV using the equation, suggested by Fowler 17 as follows:…”

“…Broadly, 2 mL volume of rectum and bladder should not receive more than 60% and 80% of the prescribed dose, respectively. 16,17 The algorithm selects the active dwell positions and determines the dwell time values to fulfill dose constraints applied on each target and organ at risk contoured. These dose constraints force the dose to drop and remain inside the acceptable zone between the minimum and the maximum dose preset.…”

Role of Perioperative Brachytherapy in the Treatment of Malignancies Involving the Skull Base and Orbit

“…5 The accepted maximal applicator surface dose was defined to be 4 times the reference isodose value, because there was no preexisting prescription data for such applications in the literature. 61 Manual dose-volume optimization was carried out and dose-volume histograms were analyzed. The inhomogeneity of the dose distribution within the target volume was adapted to the anatomic situation: critical structures were close to cold spots and potential tumor areas were covered with hot spots.…”